Bertrand Georges - Academia.edu (original) (raw)

Uploads

Papers by Bertrand Georges

Research paper thumbnail of PS-078-A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection

Journal of Hepatology, 2019

Research paper thumbnail of Totally Synthetic HSV-1 Lipopeptides Without Adjuvant, Elicit Immune Responses in Mice and Rabbits

Investigative Ophthalmology & Visual Science, 2002

Research paper thumbnail of Mixture of peptides derived from hepatitis C virus, useful as vaccinating immunogen or diagnostic reagent, binds to the commonest Class II alleles, also new peptides

Research paper thumbnail of Vecteurs et constructions d'administration d'antigenes

La presente invention a trait a des vecteurs fluorocarbones pour l'administration d'antig... more La presente invention a trait a des vecteurs fluorocarbones pour l'administration d'antigenes a des cellules cibles immunosensibles. L'invention a egalement trait a des constructions de vecteurs/antigenes fluorocarbones et l'utilisation de tels vecteurs associes a des antigenes sous forme de vaccins et d'agents immunotherapeutiques chez des animaux.

Research paper thumbnail of Identification of Novel CD4+ T Helper Peptide Epitopes from HSV Glycoprotein (gD) that Confer Protective Immunity

Research paper thumbnail of Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge

Vaccines

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective pr... more The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry. The current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity. Here, we tested a single intranasal dose of our candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (AdCOVID) in inbred, outbred, and transgenic mice. A single intranasal vaccination with AdCOVID elicited a strong and focused immune response against RBD through the induction of mucosal IgA in the respiratory tract, serum neutralizing antibodies, and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. A single AdCOVID dose resulted in immunity that wa...

Research paper thumbnail of Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial

Vaccines

Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains s... more Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains sub-optimal. Weaknesses of current vaccines include low effectiveness against mismatched strains, lack of mucosal and other effective tissue-resident immune responses, weak cellular immune responses, and insufficiently durable immune responses. The safety and immunogenicity of NasoVAX, a monovalent intranasal influenza vaccine based on a replication-deficient adenovirus type 5 platform, were evaluated in a placebo-controlled single ascending-dose study. Sixty healthy adults (18–49 years) received a single intranasal dose of 1×109 viral particles (vp), 1 × 1010 vp, or 1 × 1011 vp of NasoVAX or placebo. NasoVAX was well-tolerated and elicited robust influenza-specific systemic and mucosal immune responses. The highest NasoVAX dose and the approved Fluzone® influenza vaccine elicited comparable hemagglutination inhibition (HAI) geometric mean titers (152.8 vs. 293.4) and microneutralization ...

Research paper thumbnail of Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre

Frontiers in microbiology, 2017

In spite of there being a number of vaccines, influenza remains a significant global cause of mor... more In spite of there being a number of vaccines, influenza remains a significant global cause of morbidity and mortality. Understanding more about natural and vaccine induced immune protection against influenza infection would help to develop better vaccines. Virus specific IgG is a known correlate of protection, but other factors may help to reduce viral load or disease severity, for example IgA. In the current study we measured influenza specific responses in a controlled human infection model using influenza A/California/2009 (H1N1) as the challenge agent. Volunteers were pre-selected with low haemagglutination inhibition (HAI) titres in order to ensure a higher proportion of infection; this allowed us to explore the role of other immune correlates. In spite of HAI being uniformly low, there were variable levels of H1N1 specific IgG and IgA prior to infection. There was also a range of disease severity in volunteers allowing us to compare whether differences in systemic and local H1...

Research paper thumbnail of Mixture of Peptides from C and NS3 Proteins of the Hepatitis C Virus and Applications Thereof

Research paper thumbnail of Method of selecting HLA-DP4 ligands and the applications thereof

Research paper thumbnail of Influence du ligand peptidique sur la conformation et la stabilité des molécules du complexe majeur d'histocompatibilité de classe II

Http Www Theses Fr, 1999

Kio Kti Koi Constante de vitesse de formation du complexe intermédiaire Kio Constante de vitesse ... more Kio Kti Koi Constante de vitesse de formation du complexe intermédiaire Kio Constante de vitesse de formation du complexe d'origine à partir du complexe intermédiaire Kit Constante de vitesse de formation du complexe terminal Kti Constante de vitesse de formation du complexe intermédiaire à partir du complexe terminal

Research paper thumbnail of Use of Mixtures of Lipopeptides for Vaccine Production

Research paper thumbnail of Method for Selecting HLA-DP4 Ligands

Research paper thumbnail of Influenza Antigen Delivery Vectors and Constructs

Research paper thumbnail of Fluorocarbon-linked peptide formulation

The present invention provides an aqueous acidic formulations suitable for use in the preparation... more The present invention provides an aqueous acidic formulations suitable for use in the preparation of fluorocarbon-linked peptide pharmaceutically acceptable formulations, the aqueous formulation comprises a first fluorocarbon connecting peptide, linked to the fluorocarbon peptide a length of at least 20 amino acid residues, comprising at least 50% hydrophobic amino acid residues, having an isoelectric point of 7 or more; fluorocarbon connecting peptide present in micelles.

Research paper thumbnail of Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition

Research paper thumbnail of Antigen delivery vectors and constructs

Research paper thumbnail of Adaptation of BTI-TN5B1-4 (high five) insect cells for large-scale production in a stirred bioreactor

Research paper thumbnail of Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans

Virology journal, Jan 3, 2015

BackgroundHuman challenge models using respiratory viruses such as influenza are increasingly uti... more BackgroundHuman challenge models using respiratory viruses such as influenza are increasingly utilised in the development of novel vaccines and anti-viral modalities and can provide preliminary evidence of protection before evaluation in field trials. We describe the results of a clinical study characterising an A/H1N1 influenza challenge virus in humans.MethodsThe challenge agent, influenza A/California/2009 (H1N1), was manufactured under cGMP conditions and characterised in accordance with regulatory guidelines. A dose-ascending open-label clinical study was conducted in 29 healthy young adults screened sero-negative to the challenge strain. Subjects were intranasally inoculated with three increasing doses of virus and physician-reported signs, subjected-reported symptoms, viral shedding and immunological responses were monitored.ResultsA dose-dependent increase in clinical signs and symptoms was observed with 75% of subjects developing laboratory-confirmed illness at the highest ...

Research paper thumbnail of A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety

Vaccine, Jan 3, 2015

FP-01.1 is a novel synthetic influenza A vaccine consisting of six fluorocarbon-modified 35-mer p... more FP-01.1 is a novel synthetic influenza A vaccine consisting of six fluorocarbon-modified 35-mer peptides that encapsulate multiple CD4+ and CD8+ T-cell epitopes and is designed to induce an immune response across a broad population. FP-01.1 was evaluated for safety and immunogenicity in a randomised, double-blind, placebo-controlled, dose-escalation, phase I clinical study in healthy adult volunteers (n=49). IFNγ ELISpot assays and multicolour flow cytometry were used to characterise the immune response. FP-01.1 was safe and well tolerated at all doses tested with a similar adverse event profile in actively vaccinated subjects compared with controls. Maximum immunogenicity was in the 150μg/peptide dose group where a robust response (243 spots/million PBMC) was demonstrated in 75% subjects compared with 0% in placebo controls. All six peptides were immunogenic. FP-01.1 induced dual CD4+ and CD8+ T cell responses and vaccine-specific T cells cross-recognise divergent influenza strains...

Research paper thumbnail of PS-078-A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection

Journal of Hepatology, 2019

Research paper thumbnail of Totally Synthetic HSV-1 Lipopeptides Without Adjuvant, Elicit Immune Responses in Mice and Rabbits

Investigative Ophthalmology & Visual Science, 2002

Research paper thumbnail of Mixture of peptides derived from hepatitis C virus, useful as vaccinating immunogen or diagnostic reagent, binds to the commonest Class II alleles, also new peptides

Research paper thumbnail of Vecteurs et constructions d'administration d'antigenes

La presente invention a trait a des vecteurs fluorocarbones pour l'administration d'antig... more La presente invention a trait a des vecteurs fluorocarbones pour l'administration d'antigenes a des cellules cibles immunosensibles. L'invention a egalement trait a des constructions de vecteurs/antigenes fluorocarbones et l'utilisation de tels vecteurs associes a des antigenes sous forme de vaccins et d'agents immunotherapeutiques chez des animaux.

Research paper thumbnail of Identification of Novel CD4+ T Helper Peptide Epitopes from HSV Glycoprotein (gD) that Confer Protective Immunity

Research paper thumbnail of Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge

Vaccines

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective pr... more The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry. The current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity. Here, we tested a single intranasal dose of our candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (AdCOVID) in inbred, outbred, and transgenic mice. A single intranasal vaccination with AdCOVID elicited a strong and focused immune response against RBD through the induction of mucosal IgA in the respiratory tract, serum neutralizing antibodies, and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. A single AdCOVID dose resulted in immunity that wa...

Research paper thumbnail of Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial

Vaccines

Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains s... more Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains sub-optimal. Weaknesses of current vaccines include low effectiveness against mismatched strains, lack of mucosal and other effective tissue-resident immune responses, weak cellular immune responses, and insufficiently durable immune responses. The safety and immunogenicity of NasoVAX, a monovalent intranasal influenza vaccine based on a replication-deficient adenovirus type 5 platform, were evaluated in a placebo-controlled single ascending-dose study. Sixty healthy adults (18–49 years) received a single intranasal dose of 1×109 viral particles (vp), 1 × 1010 vp, or 1 × 1011 vp of NasoVAX or placebo. NasoVAX was well-tolerated and elicited robust influenza-specific systemic and mucosal immune responses. The highest NasoVAX dose and the approved Fluzone® influenza vaccine elicited comparable hemagglutination inhibition (HAI) geometric mean titers (152.8 vs. 293.4) and microneutralization ...

Research paper thumbnail of Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre

Frontiers in microbiology, 2017

In spite of there being a number of vaccines, influenza remains a significant global cause of mor... more In spite of there being a number of vaccines, influenza remains a significant global cause of morbidity and mortality. Understanding more about natural and vaccine induced immune protection against influenza infection would help to develop better vaccines. Virus specific IgG is a known correlate of protection, but other factors may help to reduce viral load or disease severity, for example IgA. In the current study we measured influenza specific responses in a controlled human infection model using influenza A/California/2009 (H1N1) as the challenge agent. Volunteers were pre-selected with low haemagglutination inhibition (HAI) titres in order to ensure a higher proportion of infection; this allowed us to explore the role of other immune correlates. In spite of HAI being uniformly low, there were variable levels of H1N1 specific IgG and IgA prior to infection. There was also a range of disease severity in volunteers allowing us to compare whether differences in systemic and local H1...

Research paper thumbnail of Mixture of Peptides from C and NS3 Proteins of the Hepatitis C Virus and Applications Thereof

Research paper thumbnail of Method of selecting HLA-DP4 ligands and the applications thereof

Research paper thumbnail of Influence du ligand peptidique sur la conformation et la stabilité des molécules du complexe majeur d'histocompatibilité de classe II

Http Www Theses Fr, 1999

Kio Kti Koi Constante de vitesse de formation du complexe intermédiaire Kio Constante de vitesse ... more Kio Kti Koi Constante de vitesse de formation du complexe intermédiaire Kio Constante de vitesse de formation du complexe d'origine à partir du complexe intermédiaire Kit Constante de vitesse de formation du complexe terminal Kti Constante de vitesse de formation du complexe intermédiaire à partir du complexe terminal

Research paper thumbnail of Use of Mixtures of Lipopeptides for Vaccine Production

Research paper thumbnail of Method for Selecting HLA-DP4 Ligands

Research paper thumbnail of Influenza Antigen Delivery Vectors and Constructs

Research paper thumbnail of Fluorocarbon-linked peptide formulation

The present invention provides an aqueous acidic formulations suitable for use in the preparation... more The present invention provides an aqueous acidic formulations suitable for use in the preparation of fluorocarbon-linked peptide pharmaceutically acceptable formulations, the aqueous formulation comprises a first fluorocarbon connecting peptide, linked to the fluorocarbon peptide a length of at least 20 amino acid residues, comprising at least 50% hydrophobic amino acid residues, having an isoelectric point of 7 or more; fluorocarbon connecting peptide present in micelles.

Research paper thumbnail of Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition

Research paper thumbnail of Antigen delivery vectors and constructs

Research paper thumbnail of Adaptation of BTI-TN5B1-4 (high five) insect cells for large-scale production in a stirred bioreactor

Research paper thumbnail of Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans

Virology journal, Jan 3, 2015

BackgroundHuman challenge models using respiratory viruses such as influenza are increasingly uti... more BackgroundHuman challenge models using respiratory viruses such as influenza are increasingly utilised in the development of novel vaccines and anti-viral modalities and can provide preliminary evidence of protection before evaluation in field trials. We describe the results of a clinical study characterising an A/H1N1 influenza challenge virus in humans.MethodsThe challenge agent, influenza A/California/2009 (H1N1), was manufactured under cGMP conditions and characterised in accordance with regulatory guidelines. A dose-ascending open-label clinical study was conducted in 29 healthy young adults screened sero-negative to the challenge strain. Subjects were intranasally inoculated with three increasing doses of virus and physician-reported signs, subjected-reported symptoms, viral shedding and immunological responses were monitored.ResultsA dose-dependent increase in clinical signs and symptoms was observed with 75% of subjects developing laboratory-confirmed illness at the highest ...

Research paper thumbnail of A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety

Vaccine, Jan 3, 2015

FP-01.1 is a novel synthetic influenza A vaccine consisting of six fluorocarbon-modified 35-mer p... more FP-01.1 is a novel synthetic influenza A vaccine consisting of six fluorocarbon-modified 35-mer peptides that encapsulate multiple CD4+ and CD8+ T-cell epitopes and is designed to induce an immune response across a broad population. FP-01.1 was evaluated for safety and immunogenicity in a randomised, double-blind, placebo-controlled, dose-escalation, phase I clinical study in healthy adult volunteers (n=49). IFNγ ELISpot assays and multicolour flow cytometry were used to characterise the immune response. FP-01.1 was safe and well tolerated at all doses tested with a similar adverse event profile in actively vaccinated subjects compared with controls. Maximum immunogenicity was in the 150μg/peptide dose group where a robust response (243 spots/million PBMC) was demonstrated in 75% subjects compared with 0% in placebo controls. All six peptides were immunogenic. FP-01.1 induced dual CD4+ and CD8+ T cell responses and vaccine-specific T cells cross-recognise divergent influenza strains...